PUMA expression is significantly reduced in human cutaneous melanomas
- 27 December 2004
- journal article
- Published by Springer Nature in Oncogene
- Vol. 24 (6) , 1111-1116
- https://doi.org/10.1038/sj.onc.1208374
Abstract
Cutaneous malignant melanoma is an aggressive form of skin cancer, characterized by strong chemoresistance and poor patient prognosis. The molecular mechanisms underlying its resistance to chemotherapy remain unclear but are speculated to involve the dysregulation of apoptotic pathways. In this study, we sought to determine whether PUMA (p53 upregulated modulator of apoptosis) contributes to human melanoma formation, tumor progression, and survival. We used tissue microarray and immunohistochemistry to examine PUMA expression in 107 primary melanomas, 51 metastatic melanomas, and 64 dysplastic nevi. Here we report that PUMA expression is significantly weaker in primary melanomas compared to dysplastic nevi (PP=0.001). We show that weak PUMA expression in melanoma correlates with poorer overall and disease-specific 5-year survival (PPP=0.05). Additionally, we show that exogenous PUMA expression in human melanoma cell lines (both wild type and mutant p53) results in significant apoptotic cell death. Our results suggest that PUMA expression may be an important prognostic marker for human melanoma and that adenoviral delivery of PUMA sensitizes melanoma cells to apoptosis.Keywords
This publication has 20 references indexed in Scilit:
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Apoptosis and melanoma chemoresistanceOncogene, 2003
- PUMA mediates the apoptotic response to p53 in colorectal cancer cellsProceedings of the National Academy of Sciences, 2003
- Apoptosis Regulators and Responses in Human Melanocytic and Keratinocytic CellsJournal of Investigative Dermatology, 2003
- Focus on melanomaCancer Cell, 2002
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human MelanomaJournal of Investigative Dermatology, 1999
- The chemoresistance of human malignant melanomaMelanoma Research, 1999
- Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanismsCancer Letters, 1997
- Apoptosis in cancer therapy: Crossing the thresholdCell, 1994